TJ191

TJ191 is a potent and specific anti-cancer agent that targets low TβRIII-expressing malignant T-cell leukemia/lymphoma cells. TJ191 has no affects on the proliferation of other cancer cells or normal fibroblasts or immune cells. TJ191 can be used for cancer research^[1]. In Vitro: TJ191(0-100 μM; 24 hours) exhibits pronounced anti-proliferative activity in malignant?cell?lines, the IC₅₀ values are 0.13 μM, 0.13±0.08 μM, 0.26±0.19 μM, 0.22±0.11 μM, 1.5±0.02 μM, 0.32±0.086 μM, 3.1±0.5 μM, 0.26±0.16 μM in CEM, JURKAT, MOLT-3, MOLT-4, SUP-T1, MT-2, C8166 and HSB-2 cells, respectively. But has no effects in HUT-78 (IC₅₀=17±10 μM) and MT-4 (IC₅₀=47 ± 5 μM) cells^[1].
TJ191 (0.1-3 μM; 8 or 24 hours) induces CEM cell apoptosis in a concentration- and time-dependent manner. Even at 0.3 μM, TJ191 induces the maximum apoptotic rate of 80% after 24 h^[1].